Initial Steps for the Development of a Phage-Mediated Gene Replacement Therapy Using CRISPR-Cas9 Technology
p53 gene (<i>TP53</i>) replacement therapy has shown promising results in cancer gene therapy. However, it has been hampered, mostly because of the gene delivery vector of choice. CRISPR-Cas9 technology (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein...
Main Authors: | Jordi Yang Zhou, Keittisak Suwan, Amin Hajitou |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/5/1498 |
Similar Items
-
Gene editing and therapy – A new tool: CRISPR/Cas9
by: Ashok M. Patil
Published: (2019-07-01) -
CRISPR-Cas9 mediated phage therapy as an alternative to antibiotics
by: Fikre Birhanu Balcha, et al.
Published: (2023-02-01) -
CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review
by: Emir Begagić, et al.
Published: (2024-01-01) -
Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications
by: Wei Sheng Siew, et al.
Published: (2021-08-01) -
CRISPR/Cas9: Transcending the Reality of Genome Editing
by: Sergiu Chira, et al.
Published: (2017-06-01)